For research use only. Not for therapeutic Use.
AZD-9291 mesylate (CAT: I001623) is a potent and selective inhibitor of mutated forms of the epidermal growth factor receptor (EGFR). Specifically, it targets EGFR mutations such as T790M, which is associated with resistance to traditional EGFR inhibitors. AZD-9291 mesylate acts by irreversibly binding to the mutant EGFR, inhibiting its tyrosine kinase activity and preventing downstream signaling pathways involved in tumor growth and survival. This targeted therapy has shown promising results in the treatment of non-small cell lung cancer (NSCLC) harboring EGFR mutations, offering a potential treatment option for patients with resistance to standard EGFR inhibitors.
| Catalog Number | I001623 |
| CAS Number | 1421373-66-1 |
| Synonyms | (Z)-N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylimidic acid compound with methanesulfonic acid (1:1) |
| Molecular Formula | C₂₉H₃₇N₇O₅S |
| Purity | ≥95% |
| Target | EGFR |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| Related CAS | 1421373-65-0(free base) |
| IC50 | 12.92 nM(Exon 19 deletion EGFR); 11.44 nM(L858R/T790M EGFR) |
| InChI | InChI=1S/C28H33N7O2.CH4O3S/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24;1-5(2,3)4/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32);1H3,(H,2,3,4) |
| InChIKey | FUKSNUHSJBTCFJ-UHFFFAOYSA-N |
| SMILES | CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC.CS(=O)(=O)O |
| Reference | 1: Stinchcombe TE. AZD9291 in epidermal growth factor receptor |
